HIF1A and bone metastasis: Considering that HIF-1α is a crucial partner of ASH1L in metastatic cells and agents targeting HIF-1α are currently under clinical investigation38,53, we also evaluated the effects of HIF-1α inhibitor PX-478 in our preclinical model of bone metastasis.